-
Mashup Score: 2
Giuseppe Lombardi, MD, PhD, Veneto Institute of Oncology, Padua, Italy, discusses the latest findings and results in neuro-oncology, including updates from the Phase III INDIGO (NCT04164901) trial, a Phase I study (NCT04324840) into the combination of trotabresib and temozolomide, as well as prognosis biomarkers in gliomas and pemigatinib for the treatment of patients with meningioma. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
March is #braintumourawarenessmonth 📣 🧠And we are passionate about bringing you the latest news & updates - take a look at this NEW: #ESMO2023 interview | Latest updates in #trials investigating treatments of #neurologicalmalignancies 🇪🇸 🎥 👉 https://t.co/U8qag7AlMV